SCHEMBL15480217

SCHEMBL15480217

c1ccc(-n2c3ccccc3c3ccc(-c4ccc5c6ccccc6n(-c6ccc(-c7cc8ccccc8c8ccccc78)cc6)c5c4)cc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
ATM Q13315 1/20 0.51
CYP11B1 P15538 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 1/20 0.37
MPI P34949 1/20 0.37
HDAC4 P56524 1/20 0.37
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
TSHR P16473 1/20 0.35
IL1R1 P14778 1/20 0.35
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PGR P06401 1/20 0.34
HTT P42858 1/20 0.34
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15480130 0.96 KDM4E (0.47) KDM4EL3MBTL1ATMCYP11B1ALDH1A1
SCHEMBL15480098 0.96 KDM4E (0.47) KDM4EL3MBTL1ATMCYP11B1ALDH1A1
SCHEMBL19420256 0.95 KDM4E (0.46) KDM4EL3MBTL1ATMCYP11B1ALDH1A1
SCHEMBL23370543 0.92 L3MBTL1 (0.49) KDM4EL3MBTL1ATMCYP11B1ALDH1A1
SCHEMBL23370417 0.92 L3MBTL1 (0.49) KDM4EL3MBTL1ATMCYP11B1ALDH1A1
SCHEMBL20275369 0.91 KDM4E (0.51) KDM4EL3MBTL1ATMCYP11B1ALDH1A1
SCHEMBL20655087 0.91 KDM4E (0.43) KDM4EL3MBTL1ATMCYP11B1ALDH1A1
SCHEMBL23370545 0.91 KDM4E (0.45) KDM4EL3MBTL1ATMCYP11B1ALDH1A1
SCHEMBL23370422 0.91 KDM4E (0.45) KDM4EL3MBTL1ATMCYP11B1ALDH1A1
SCHEMBL23370501 0.91 L3MBTL1 (0.45) KDM4EL3MBTL1ATMCYP11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210151683-A1 LIGHT-EMITTING ELEMENT, AND DISPLAY, ILLUMINATOR, AND SENSOR EACH INCLUDING SAME TORAY INDUSTRIES, INC. (JP) 2021-05-20 US disclosed
US-20160268517-A1 BISCARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-09-15 US disclosed
US-20160268517-A1 BISCARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-09-15 US disclosed
US-20150249219-A1 BISCARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2015-09-03 US disclosed
US-20150249219-A1 BISCARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2015-09-03 US disclosed
US-20140048784-A1 BISCARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2014-02-20 US disclosed
US-20140048784-A1 BISCARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160268517-A1 BISCARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME L1CAM, CCNT1, CCNA1 KDM4E 2191/4885L3MBTL1 30/4885ATM 4082/4885
US-20150249219-A1 BISCARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME L1CAM, CCNT1, CCNA1 KDM4E 2205/4885L3MBTL1 29/4885ATM 4082/4885
US-20210151683-A1 LIGHT-EMITTING ELEMENT, AND DISPLAY, ILLUMINATOR, AND SENSOR EACH INCLUDING SAME CBR3, INTS9, CBR1 KDM4E 1196/4885L3MBTL1 208/4885ATM 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.